NCT06111781 - The SUGAR Study; SBRT and Relugolix) for Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions

Prostate Cancer

Interventions

DRUG

Relugolix 120 MG [Orgovyx]

ORGOVYX will be initiated with a loading dose of 360 mg on the first day and continue treatment with a 120 mg dose taken orally once daily at approximately the same time each day. Total length of treatment will be 30 days.

RADIATION

SBRT standard of care radiotherapy treatment

SBRT is a standard-of-care radiotherapy treatment for intermediate-risk prostate cancer.

Trial Locations (2)

10017

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

06520

RECRUITING

Yale Cancer Center, New Haven